The largest database of trusted experimental protocols

Methadone

Methadone is a synthetic opioid medication used primarily for the treatment of opioid addiction and chronic pain.
It acts as a long-acting mu-opioid receptor agonist, reducing withdrawal symptoms and cravings associated with opioid dependence.
Methadone is typically administered orally and has a longer half-life compared to other opioids, allowing for once-daily dosing.
It is an essential component of medication-assisted treatment (MAT) for opioid use disorder, helping individuals achieve and maintain recovery.
Methadone's use is closely monitored due to its potent analgesic and euphoric effects, as well as the risk of overdose and respiratory depression.
Proper dosing and medical supervision are crucial to ensure the safe and effective use of methadone in clinical settings.

Most cited protocols related to «Methadone»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Buprenorphine Codeine Drug Overdose Heroin Metabolic Detoxication, Drug Methadone Morphine N-nitrosoiminodiacetic acid Opioids Oxycodone Relapse Safety TimeLine Treatment Protocols Urine Visual Analog Pain Scale

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Chronic Pain Clinical Trials Data Monitoring Committees Conception Contraceptive Methods Drug Abuse Ethics Committees, Research Hypersensitivity Inpatient Metabolic Detoxication, Drug Methadone N-nitrosoiminodiacetic acid Opioids Opioid Use Disorder Outpatients Safety Substance Use Disorders Transaminases Woman
Two investigators independently reviewed the titles and abstracts identified in the search and retrieved articles to determine eligibility and to extract study data. Disagreements or uncertainties were resolved by consensus with an additional investigator.
For each eligible study, we retrieved information on baseline population characteristics, including study location, sex and age distribution, primary opioid of misuse, and prevalence of opioid injection, non-opioid drug use, HIV infection, and psychiatric and medical comorbidity; number of cohort participants entering opioid substitution treatment during the study period (untreated participants and those under other types of treatment were excluded); treatment features, including drug type (methadone or buprenorphine), average daily dose, induction method (inpatient or ambulatory), and provider (addiction medicine specialist or general practitioner); and main follow-up characteristics, including calendar period, average length of follow-up from the start of maintenance treatment (excluding any previous detoxification period), loss to follow-up, and mortality outcomes. We also registered detailed information on the number of deaths, person years at risk, and mortality rates from all causes and overdose during follow-up periods in and out of treatment and, whenever possible, during specific time intervals since treatment initiation and cessation. Finally, we registered information on first and subsequent treatment episodes (table A in appendix 2) and on completeness of treatment (table B in appendix 2).
We specifically designed a quality assessment form based on standardised and extensively used instruments: the methodology checklist for cohort studies developed by the Scottish Intercollegiate Guidelines Network14 and the checklist for drug related studies developed by the National Drug and Alcohol Research Centre, Australia.15 The design process, based on a thorough review of the above sources, included the development of different proposals, discussion of their appropriateness, and final agreement among the authors. The final version comprised separate sections according to the study design and was based on a “star system” score approach,16 including a general appraisal of external and internal validity and of the biases relevant to cohort studies, plus an ad hoc assessment of reporting for studies on mortality during and after opioid substitution treatment (appendix 3).
Publication 2017
Buprenorphine Drug Overdose Eligibility Determination Ethanol HIV Infections Inpatient Metabolic Detoxication, Drug Methadone Opiate Substitution Treatment Opioid Misuse Opioids Pharmaceutical Preparations
Participants were recruited from individuals enrolled in one of the methadone maintenance programs of the APT Foundation, the largest provider of methadone maintenance services in New Haven, Connecticut. Participants were English-speaking adults, stabilized on methadone (same dose>2 months), who met DSM-IV criteria for current (within the past 30 days) cocaine dependence. As in our previous trial, exclusion criteria were minimized in order to facilitate recruitment of a broad and clinically representative group of individuals enrolled in this setting. Thus, individuals were excluded only if (1) they failed to meet DSM-IV criteria for current cocaine dependence, (2) had an untreated/unstabilized psychotic disorder or had current suicidal/homicidal ideation such that more intensive treatment was indicated, or (3) could not read at a 6th grade level (required for provision of written informed consent and completion of assessment instruments).
As shown in the CONSORT diagram (Figure 1), 101 of the 154 individuals screened were determined to be eligible for the study, provided written informed consent and were randomized. Following description of the study and provision of written informed consent approved by the Yale University School of Medicine Human Investigations Committee, participants were randomized to either TAU or CBT4CBT, using a computerized urn randomization program (29 ) to balance treatment groups with respect to gender, ethnicity, education level, and frequency of cocaine use at baseline.
Publication 2014
Adult Cocaine Cocaine Dependence Ethnicity Gender Homo sapiens Investigational New Drugs Methadone Psychotic Disorders
The target group will be PWID receiving integrated substance use disorder treatment and care from involved clinics in Bergen and Stavanger who are chronically infected with HCV and eligible for treatment according to national guidelines.
Department of Addiction Medicine at Haukeland University Hospital in Bergen have adopted an integrated treatment and care model for PWID receiving OAT. In Bergen, OAT outpatient clinics have been established in each district where the patients are followed up by health and social workers on a nearly daily basis with observed intake of the OAT medications such as buprenorphine or methadone [17 ]. Every month, the OAT clinics have a total of 6000 visits among the approximately 500 patients. This group of patients have a large morbidity burden and have to a limited extent been able to get access to other standard health care. Each of the OAT outpatient clinics is staffed by a consultant and a physician/ specialist registrar in addiction medicine in addition to nurses, social workers, and psychologists. A close collaboration has been established between the Department of Addiction Medicine and the Agency for addiction and mental health in Bergen municipality, who is responsible for the care in several of the primary health clinics for PWID in Bergen. Clinics for PWID in the Stavanger area have a relatively similar structure and are responsible for the OAT treatment of approximately 460 patients within their area. People receiving OAT in Norway are generally prescribed buprenorphine or methadone, to some degree additional benzodiazepines but rarely other opioids. The treatment model in Bergen and Stavanger is a well-suited platform to test integration of HCV treatment aiming to improve the health and life span of a vulnerable group, and at the same time gathering knowledge which traditionally have been difficult to obtain.
Full text: Click here
Publication 2019
Addictive Behavior Benzodiazepines Buprenorphine Consultant Mental Health Methadone Nurses Opioids Patients Pharmaceutical Preparations Physicians Substance Use Disorders

Most recents protocols related to «Methadone»

Exposure to opioids was captured using prescription information available in the pharmacy claims (e.g., medication name, fill date, days supplied). Opioid exposure was examined at monthly intervals from each person’s study entry date to their drop in health plan enrollment or end of study period, whichever came first. Individuals were included in the analysis per month if they had enrollment for that entire month. Opioid exposure was determined by an outpatient pharmacy fill for a product containing hydrocodone, oxycodone, tramadol, codeine, morphine, fentanyl, and “other”, which included hydromorphone, buprenorphine, propoxyphene, oxymorphone, methadone, dihydrocodeine, levorphanol tartrate, meperidine hydrochloride, opium, pentazocine, and tapentadol.
The timing of opioid exposure was based on the date of prescription and number of days supplied, which allowed for the determination of monthly exposure as binary (yes/no) and number of days supplied. To standardize the number of days supplied per month, the proportion of each month exposed was calculated as the days supplied divided by the number of days in that month. This study did not standardize doses across opioid types (e.g., oral morphine equivalents) given the variability in suggested conversion factors [24 (link)]. Further, it is unknown if the proportion of opioid prescriptions by type differs for adults with and without CP, and how variation in conversion factors could impact interpretations. Therefore, this study focused on measures of opioid exposure as exposed/not exposed, the number of days supplied, and the proportion of opioid prescriptions by type.
Publication 2023
Adult Buprenorphine Codeine dihydrocodeine Fentanyl Health Planning Hydrocodone Hydromorphone Meperidine Hydrochloride Methadone Morphine Opioids Opium Outpatients Oxycodone Oxymorphone Pentazocine Pharmaceutical Preparations Prescriptions Propoxyphene Tapentadol Tartrate, Levorphanol Tramadol
The survey collected sociodemographic information including age-group, gender identity, race/ethnicity, health insurance type, monthly out-of-pocket payments for methadone, and participant MMT clinic state and city. It also collected self-reported information on take-home dose quantities, in-person clinic visits, toxicological screens, and counseling attendance.
Participant take-home dose quantities were measured categorically as: no take-home doses, 1 per week, 2 per week, 3 per week, 4 per week, 5 per week, 6 or 7 (one week), 13 or 14 (two weeks), and 27 or 28 (one month). Overall clinic attendance was measured categorically as every day, 6 times a week, 5 times a week, 4 times a week, 3 times a week, 2 times a week, once a week, twice a month, or once a month. Counseling attendance was also measured categorically as: daily, 3 times a week, 2 times a week, weekly, 6 times a month, 3 times a month, 2 times a month, once a month, once every 3 months, and none. Method of counseling attendance was also measured categorically as: not required to attend counseling services, in person, through telehealth, by telephone, and none. Information regarding how often toxicological screens were required was measured as, “never,” “1–2 times a month,” “2–5 times a month,” “5–7 times a month,” “7–10 times a month,” “10–15 times a month,” “20 +, ” and “other” as a write-in response. Items where participants indicated they did not know or if they left the question blank, that response was considered missing. Categories were established by consulting with community members and with considerations toward the balance of sample size between groups. The survey included two write-in response questions: “What has your clinic done to maintain 6-foot social distancing between people?” and “Is there anything else you would like to tell us about your clinic's practices during COVID-19?”.
Full text: Click here
Publication 2023
Age Groups Clinic Visits Counseling COVID 19 Ethnicity Foot Gender Identity Health Insurance Methadone Telemedicine
Consistent with the community-driven research (CDR) approach, this project was designed and led by people directly impacted by methadone treatment policies [47 (link), 58 (link)]. The first author, in collaboration with National Survivors Union (NSU), the national union for people who use drugs in the United States, used a CDR [47 (link)] approach to the study. CDR is particularly useful for research with marginalized populations who often have negative experiences with researchers [11 (link)]. In the CDR model, members of the impacted community are considered fundamental drivers of all aspects of the research, from initiating and developing the research questions to data interpretation, analysis, and dissemination phases of the project [9 (link)]. Our use of the CDR model emphasizes leadership capacity development for community members with living experience [58 (link)]. Since the early stages of the project were unfunded, in lieu of compensating directly impacted collaborators, the first author provided NSU members with training and contributed to NSU activities unrelated to the research.
Data for these analyses come from a national online survey NSU conducted to discover if and how MMT in-person requirements were relaxed throughout the country. The cross-sectional survey, written in English, contained 28 questions including two write-in response questions (Appendix). NSU members designed the survey questions based on their MMT experiences during COVID-19 or the experiences of methadone patients in their community. Next, an academic researcher member phrased the questions, which six NSU methadone workgroup members evaluated over four two-hour sessions and further refined. Two members tested the survey prior to distribution for inclusive and accessible language, survey length, and potentially stigmatizing or traumatizing questions. As a result of testing, the survey was shortened, phrasing and word choice changed for several questions, and write-in questions were added.
The survey was conducted from June 7, 2020, to July 15, 2020. NSU members used targeted sampling methods [46 (link)] to recruit a convenience sample of methadone patients through drug use and methadone patient social media groups (Facebook, Reddit, Web site pop-ups, and Twitter). No respondents were compensated for participation because the CDR project was unfunded. All questions were optional. The anonymous survey was short (approximately 7 min) in respect of participants’ time.
In total, 455 people participated in the survey. The study inclusion criteria were self-reported current methadone treatment in the United States. Responses were checked to ensure respondents submitted only one response. We omitted respondents who did not complete the survey or reported that they were not MMT patients in the United States. The final analytic sample comprised 392 participants from 219 cities (1 to 9 participants per city) in 43 states and Washington D.C.
Full text: Click here
Publication 2023
COVID 19 Inclusion Bodies Methadone Patients Pharmaceutical Preparations Survivors
Descriptive statistics were calculated for changes in required clinic visits and drug screening frequency, number of take-home doses, and counseling during COVID-19. States were grouped into four regions following the United States Census Bureau definition [67 ]. Insurance was grouped into three categories: private, government, and none. The private insurance category includes company healthcare plans, insurance purchased through the Affordable Care Act Health Insurance Marketplace (“Obamacare”), and self-funded insurance. The government-funded insurance category includes Medicaid, Medicare, Tricare, MassHealth, New Jersey family care, and state and county grants. People who identified two race/ethnicity categories were counted according to their minority category (for example, someone who identified as Black and white was counted as Black).
We used logistic regression models to examine factors associated with two outcomes related to in-person clinic attendance. The first outcome was whether someone received increased methadone take-home doses. Participants who did not report increased take-home doses during COVID-19 were coded as 0. Participants who reported any increase in take-home doses during COVID-19 were coded as 1. The second outcome was whether someone reported decreased in-person counseling. Participants who reported switching from in-person counseling prior to COVID-19 to telehealth or to no counseling during COVID-19 were coded as 1. Anyone who reported that they maintained in-person counseling or switched to in-person counseling during COVID-19 was coded as 0.
We looked at the associations of these two outcomes with the covariates of gender, age, region, methadone cost, and time in MMT in univariate logistic regression outcomes. We fitted a second set of logistic regressions for the same outcomes and covariates, and we accounted for time on MMT by including it as a covariate. Those who had missing data were excluded from the regression analyses.
Full text: Click here
Publication 2023
Clinic Visits COVID 19 Ethnicity Gender Health Insurance Exchanges Infantile Neuroaxonal Dystrophy Methadone Minority Groups Telemedicine
Data analysis was performed from January to September 2022. Analyses were conducted by person-year. After conducting descriptive analyses and χ2 tests, we fit generalized estimating equations with robust SEs assuming an exchangeable correlation structure using SAS statistical software version 9.4 (SAS Institute) to account for correlated outcomes of individuals in the data for multiple years. Two-tailed P < .05 was considered to denote statistical significance. Models adjusted for the confounding variables of age, gender, race and ethnicity (identified via database; race and ethnicity were included to isolate their associations with disability to the extent possible), urban residence, SUD other than OUD in the year, mental disorder in the year, eligibility year, and living in an institution for at least 2 months of the year, to be consistent with the literature. Model 1 included any disability as a dichotomous independent variable. Model 2 included each type of disability, also dichotomous with each compared with persons without that disability, as some enrollees have more than 1 type. Full models are in eTables 4, 5, 6, and 7 in Supplement 1. We also modeled type of medication by disability status and type among those receiving buprenorphine or methadone.
Full text: Click here
Publication 2023
Buprenorphine Dietary Supplements Disabled Persons Eligibility Determination Ethnicity Gender Mental Disorders Methadone Pharmaceutical Preparations

Top products related to «Methadone»

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States
Methadone is a laboratory reagent used as an internal standard in the analysis of opioid compounds. It is a synthetic opioid that can be utilized to quantify the presence and concentration of related substances in analytical samples.
Sourced in United Kingdom, United States
Methadone hydrochloride is a synthetic opioid compound used as a laboratory reagent. It is a white, crystalline powder with a melting point of approximately 235-240°C. Methadone hydrochloride is soluble in water, alcohol, and other polar solvents. It is commonly used in various analytical and research applications.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in Germany, United Kingdom, Spain, United States, France, Canada, Australia, Japan, Poland, Switzerland, Italy
Metacam is a veterinary pharmaceutical product manufactured by Boehringer Ingelheim. It contains the active ingredient meloxicam, which is a nonsteroidal anti-inflammatory drug (NSAID).
Sourced in United States, United Kingdom, China, Germany, Belgium, Canada, France, India, Australia, Portugal, Spain, New Zealand, Ireland, Sweden, Italy, Denmark, Poland, Malaysia, Switzerland, Macao, Sao Tome and Principe, Bulgaria
Methanol is a colorless, volatile, and flammable liquid chemical compound. It is commonly used as a solvent, fuel, and feedstock in various industrial processes.
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
Sourced in United States, United Kingdom, China, Belgium, Germany, Canada, Portugal, France, Australia, Spain, Switzerland, India, Ireland, New Zealand, Sweden, Italy, Japan, Mexico, Denmark
Acetonitrile is a highly polar, aprotic organic solvent commonly used in analytical and synthetic chemistry applications. It has a low boiling point and is miscible with water and many organic solvents. Acetonitrile is a versatile solvent that can be utilized in various laboratory procedures, such as HPLC, GC, and extraction processes.
Sourced in Finland, United States, Sweden
Dexdomitor is a veterinary prescription-only medication used as a sedative and analgesic in various animal species. It contains the active ingredient dexmedetomidine hydrochloride, which is an alpha-2 adrenoceptor agonist. Dexdomitor is administered by injection and primarily affects the central nervous system to induce a state of calm and relaxation.

More about "Methadone"

Methadone is a synthetic opioid medication that has become a crucial component in the treatment of opioid addiction and chronic pain management.
This long-acting mu-opioid receptor agonist helps alleviate withdrawal symptoms and cravings associated with opioid dependence, making it an essential part of medication-assisted treatment (MAT) programs.
Methadone hydrochloride, the salt form of the drug, is typically administered orally and has a longer half-life compared to other opioids, allowing for once-daily dosing.
The use of methadone is closely monitored due to its potent analgesic and euphoric effects, as well as the risk of overdose and respiratory depression.
Proper dosing and medical supervision are crucial to ensure the safe and effective use of methadone in clinical settings.
Researchers and healthcare professionals may utilize tools like SAS version 9.4, Stata 12.0, and various chemical compounds such as DMSO, Metacam, Methanol, and Acetonitrile to enhance the reproducibility and accuracy of methadone-related studies.
By leveraging the insights gained from the MeSH term description and Metadescription, researchers can optimize their methadone research using AI-driven platforms like PubCompare.ai.
These innovative solutions can help users easily locate protocols from literature, preprints, and patents, while utilizing AI-driven comparisons to identify the best protocols and products.
Streamlining the research process in this manner can lead to more informed decisions and advancements in the field of methadone treatment and opioid use disorder management.